PD-1

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, Paméla Thébault, Shirin Kazemi, Jennifer E. Friedmann, Jeanne Dionne, Jean-François Cailhier, Karl Bélanger, Jean-Pierre Ayoub, Huy Le, Caroline Lambert, Jida El-Hajjar, Léon C. van Kempen, Alan Spatz, Wilson H. Miller

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 83; DOI: 10.1186/s40425-017-0290-x
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
Samantha N. Reiss, Prakirthi Yerram, Lisa Modelevsky, Christian Grommes

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 99; DOI: 10.1186/s40425-017-0302-x
Adoptive cell therapy using PD-1⁺ myeloma-reactive T cells eliminates established myeloma in mice
Weiqing Jing, Jill A. Gershan, Grace C. Blitzer, Katie Palen, James Weber, Laura McOlash, Matthew Riese, Bryon D. Johnson

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 51; DOI: 10.1186/s40425-017-0256-z
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31^stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016
Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky, Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey, Charles G. Drake, Gordon J. Freeman, Ramy Ibrahim, Salil Patel, Daniel S. Chen

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 50; DOI: 10.1186/s40425-017-0253-2
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suthee Rapisuwon, Michael Postow, Michael A. Davies, Zeynep Eroglu, Douglas Johnson

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 8; DOI: 10.1186/s40425-017-0210-0
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation
James Godfrey, Michael R. Bishop, Sahr Syed, Elizabeth Hyjek, Justin Kline

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 11; DOI: 10.1186/s40425-017-0211-z
Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy
Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb, William J. Murphy

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 33; DOI: 10.1186/s40425-017-0235-4
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
Kathryn E. Beckermann, Pradeep C. Jolly, Ju Y. Kim, Jennifer Bordeaux, Igor Puzanov, W. Kimryn Rathmell, Douglas B. Johnson

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 1; DOI: 10.1186/s40425-016-0206-1
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Raju R Raval, Andrew B Sharabi, Amanda J Walker, Charles G Drake, Padmanee Sharma

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 14; DOI: 10.1186/2051-1426-2-14

Main menu

PD-1

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

PD-1

Pages